Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of delafloxacin versus vancomycin + aztreonam in acute bacterial skin and skin structure infections
2012-001767-71Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Apr 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) and bacterial infections of skin and subcutaneous tissue (SSTI) comparing Delafloxacin with Vancomycin + aztreonam (2 arms). Primary endpoint: Investigator-assessed response of signs and symptoms of infection at the Follow-up Visit. Started Apr 2013; status: completed.
02
Drugs
delafloxacinvancomycinaztreonam
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)bacterial infections of skin and subcutaneous tissue (SSTI)
Beyond the preview
Go deeper on 2012-001767-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001767-71.